Modality
Fusion Protein
MOA
HER2
Target
CDK4/6
Pathway
Epigenetic
MCCPVDMD
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Oct 2025
Phase 2Current
NCT08808600
83 pts·DMD
2018-07→2025-10·Not yet recruiting
83 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-056mo agoPh3 Readout· DMD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-10-05 · 6mo ago
DMD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08808600 | Phase 2/3 | DMD | Not yet recr... | 83 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |